Edition:
India

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

5.20USD
2:29am IST
Change (% chg)

$-0.17 (-3.26%)
Prev Close
$5.38
Open
$5.35
Day's High
$5.40
Day's Low
$5.18
Volume
119,064
Avg. Vol
265,878
52-wk High
$21.15
52-wk Low
$2.80

Select another date:

Thu, Nov 9 2017

BRIEF-Otonomy reports third quarter loss of $0.69 per share

* Otonomy reports third quarter 2017 financial results and provides corporate update

BRIEF-Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease

* Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease

BRIEF-Otonomy Inc says ‍non-commercial workforce reduced by one-third​

* Otonomy Inc - ‍* non-commercial workforce reduced by one-third​

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc said on Wednesday it suspended developing its drug for Meniere's disease, a chronic disorder of the inner ear, after it failed a late-stage trial, sending the drugmaker's shares plummeting in premarket trade.

BRIEF-Otonomy reports results for Averts-1 phase 3 trial for Otividex

* Says ‍company is withdrawing spending guidance for year pending review of product pipeline plans

Otonomy's ear disease drug fails late-stage study

Aug 30 U.S. drugmaker Otonomy Inc said on Wednesday its drug to treat Ménière's disease, a chronic disorder of the inner ear, missed the main goal in a late-stage study.

BRIEF-Otonomy ‍reaffirms qtrly ‍net loss per share $0.77​

* Otonomy reports second quarter 2017 financial results and provides corporate update

BRIEF-FDA accepts Otonomy's expanded label application for Otiprio

* Otonomy announces FDA acceptance of Otiprio supplemental new drug application filing for acute otitis externa

BRIEF-Otonomy announces successful end-of-phase 2 review by FDA for Otiprio

* Otonomy announces successful end-of-Phase 2 review by FDA for Otiprio® in acute otitis media with tympanostomy tubes

Select another date: